The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer
Abstract
PURPOSE: To determine whether long-term survivors of metastatic testicular cancer have an increased risk of cardiovascular morbidity more than 10 years after chemotherapy. PATIENTS AND METHODS: Eighty-seven patients treated with cisplatin-containing chemotherapy before 1987 who were in remission for at least 10 years and whose ages were ≤ 50 years at the time of analysis were evaluated for the occurrence of cardiovascular events. Sixty-two of 87 patients were additionally evaluated for cardiac damage and cardiovascular risk factors. Their cardiovascular risk profile was compared with that of 40 patients with comparable age and follow-up duration treated with orchidectomy only for stage I disease. RESULTS: Major cardiac events were found in five (6%) of the 87 patients (age at time of event, 30 to 42 years; time after chemotherapy, 9 to 16 years): two with myocardial infarction and three with angina pectoris with proven myocardial ischemia. An increased observed-to-expected ratio of 7.1 (95% confidence interval, 1.9 to 18.3) for coronary artery disease, as compared with the general male Dutch population, was found. In addition, one patient experienced a cerebrovascular accident. Exercise ECG did not reveal cases of subclinical coronary artery disease. Echocardiography showed normal systolic left ventricular function in most patients, but diastolic left ventricular function was disturbed in 33% of the patients. Of 62 chemotherapy patients, 79% had hypercholesterolemia, 39% had hypertension, 25% still experienced Raynaud’s phenomenon, and 22% had microalbuminuria. Compared with patients with stage I disease, the chemotherapy patients had higher blood pressure and higher total cholesterol and triglyceride levels and were more insulin-resistant. CONCLUSION: In long-term survivors of metastatic testicular cancer, we observed a significantly increased risk for occurrence of cardiac events accompanied by a persisting unfavorable cardiovascular risk profile. Accurate follow-up, focused on cardiovascular complications and aimed at intervention in these young cancer survivors, seems to be important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
Koren, M. J., Devereux, R. B., Casale, P. N., Savage, D. D., & Laragh, J. H. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-5-345 · Cited by 2,366
Kuczmarski, R. J. (1994) · JAMA · doi:10.1001/jama.272.3.205 · Cited by 2,362
Williams, S. D., Birch, R., Einhorn, L. H., Irwin, L., Greco, F. A., & Loehrer, P. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162302 · Cited by 1,170
MICROALBUMINURIA AS PREDICTOR OF VASCULAR DISEASE IN NON-DIABETIC SUBJECTS
Yudkin, J., Forrest, R., & Jackson, C. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92657-8 · Cited by 847
Microalbuminuria as predictor of increased mortality in elderly people.
Damsgaard, E. M., Frøland, A., Jørgensen, O. D., & Mogensen, C. E. (1990) · BMJ · doi:10.1136/bmj.300.6720.297 · Cited by 609
Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer
Travis, L. B., Curtis, R. E., Fraumeni, J. F., Boice, J. D., Storm, H., Andersson, M., Hall, P., Bergfeldt, K., Holowaty, E., Clarke, E. A., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.19.1429 · Cited by 488
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., Hagerty, K. L., Somerfield, M. R., & Vaughn, D. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.9777 · Cited by 793
Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Cavallin-Ståhl, E., et al. (2008) · European Urology · doi:10.1016/j.eururo.2007.12.024 · Cited by 617
Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer
Huddart, R. A., Norman, A., Shahidi, M., Horwich, A., Coward, D., Nicholls, J., & Dearnaley, D. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.173 · Cited by 547
van den Belt-Dusebout, A. W., de Wit, R., Gietema, J. A., Horenblas, S., Louwman, M. W. J., Ribot, J. G., Hoekstra, H. J., Ouwens, G. M., Aleman, B. M. P., & van Leeuwen, F. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5296 · Cited by 453
Self-citationTesticular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450
Haugnes, H. S., Wethal, T., Aass, N., Dahl, O., Klepp, O., Langberg, C. W., Wilsgaard, T., Bremnes, R. M., & Fosså, S. D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.9362 · Cited by 404
Horwich, A., Shipley, J., & Huddart, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68305-0 · Cited by 398
Cardiotoxicity of cytotoxic drugs
Schimmel, K. J. M., Richel, D. J., van den Brink, R. B. A., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.003 · Cited by 391
Increased Risk of Ischemic Stroke After Radiotherapy on the Neck in Patients Younger Than 60 Years
Dorresteijn, L. D. A., Kappelle, A. C., Boogerd, W. J., Klokman, W. J., Balm, A. J. M., Keus, R. B., van Leeuwen, F. E., & Bartelink, H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.282 · Cited by 385
Medical Treatment of Advanced Testicular Cancer
Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 370
Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer
van den Belt-Dusebout, A. W., Nuver, J., de Wit, R., Gietema, J. A., ten Bokkel Huinink, W. W., Rodrigus, P. T. R., Schimmel, E. C., Aleman, B. M. P., & van Leeuwen, F. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7193 · Cited by 345
Self-citationKenney, L. B., Laufer, M. R., Grant, F. D., Grier, H., & Diller, L. (2001) · Cancer · doi:10.1002/1097-0142(20010201)91:3<613::aid-cncr1042>3.0.co;2-r · Cited by 327
Long-Term and Late Effects of Germ Cell Testicular Cancer Treatment and Implications for Follow-Up
Haugnes, H. S., Bosl, G. J., Boer, H., Gietema, J. A., Brydøy, M., Oldenburg, J., Dahl, A. A., Bremnes, R. M., & Fosså, S. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4431 · Cited by 294
Self-citationTesticular Cancer Survivorship: Research Strategies and Recommendations
Travis, L. B., Beard, C., Allan, J. M., Dahl, A. A., Feldman, D. R., Oldenburg, J., Daugaard, G., Kelly, J. L., Dolan, M. E., Hannigan, R., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq216 · Cited by 294
Self-citationMortality After Cure of Testicular Seminoma
Zagars, G. K., Ballo, M. T., Lee, A. K., & Strom, S. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.205 · Cited by 286
Tandstad, T., Dahl, O., Cohn-Cedermark, G., Cavallin-Stahl, E., Stierner, U., Solberg, A., Langberg, C., Bremnes, R. M., Laurell, A., Wijkstrøm, H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8953 · Cited by 262
Cardiovascular disease in cancer survivors
Okwuosa, T. M., Anzevino, S., & Rao, R. (2017) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2016-134417 · Cited by 97
Health Behaviors and Depressive Symptoms in Testicular Cancer Survivors
Shinn, E. H., Basen-Engquist, K., Thornton, B., Spiess, P. E., & Pisters, L. (2007) · Urology · doi:10.1016/j.urology.2006.12.022 · Cited by 59
Objective and subjective predictors of cancer-related stress symptoms in testicular cancer survivors
Fleer, J., Sleijfer, D., Hoekstra, H., Tuinman, M., Klip, E., & Hoekstra-Weebers, J. (2006) · Patient Education and Counseling · doi:10.1016/j.pec.2005.12.009 · Cited by 49
“009 survivor [1,2].”
BackgroundSelf-citationSurvivorship After Childhood, Adolescent, and Young Adult Cancer
Tonorezos, E. S., & Oeffinger, K. C. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e31818f5aba · Cited by 21
Early ageing after cytotoxic treatment for testicular cancer and cellular senescence: Time to act
Lubberts, S., Meijer, C., Demaria, M., & Gietema, J. A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102963 · Cited by 19
Self-citation
Metadata
- Authors
- Meinardi, M. T., Gietema, J. A., van der Graaf, W. T. A., van Veldhuisen, D. J., Runne, M. A., Sluiter, W. J., de Vries, E. G. E., Willemse, P. B. H., Mulder, N. H., van den Berg, M. P., Koops, H. S., & Sleijfer, D. T.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-04-08
- Volume
- 18
- Issue
- 8
- Pages
- 1725-1732
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2175942611
- Cited by
- 489
- References
- 28
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.